Key Clinical Formulas & Scores
7 questions, each scored 0-5 (total 0-35)
1. Incomplete emptying (frequency of sensation of not emptying bladder completely)
2. Frequency (voiding every โค2 hours)
3. Intermittency (stopping and starting again)
4. Urgency (difficulty postponing voiding)
5. Weak stream
6. Straining to void
7. Nocturia (number of times waking at night to void)
Score: 0-7 = mild, 8-19 = moderate, 20-35 = severe
Plus QoL question: 0-6 (delighted to terrible)
Biopsy: primary pattern + secondary pattern (each graded 1-5)
Grade Group 1: Gleason โค6 (3+3) โ low risk
Grade Group 2: Gleason 3+4=7 โ intermediate
Grade Group 3: Gleason 4+3=7 โ intermediate-high
Grade Group 4: Gleason 4+4=8 โ high risk
Grade Group 5: Gleason 9-10 (4+5, 5+4, 5+5) โ very high risk
Gleason 5 = no glandular differentiation (sheets, cords, single cells)
Same as IPSS โ measures LUTS severity
Voiding symptoms (obstructive): weak stream, intermittency, straining, incomplete emptying
Storage symptoms (irritative): frequency, urgency, nocturia
Management thresholds: IPSS โค7 = watchful waiting, 8-19 = medical therapy (ฮฑ-blocker ยฑ 5ฮฑ-reductase inhibitor), โฅ20 or complications = surgical (TURP, HoLEP)
Very Low: PSA <10, Gleason โค6, T1-T2a, <3 positive cores, <50% cancer per core
Low: PSA <10, Gleason โค6, T1-T2a
Intermediate: PSA 10-20 OR Gleason 7 OR T2b-T2c
Favorable Intermediate: โค50% cores positive, 1 intermediate factor
Unfavorable Intermediate: >50% cores positive, Gleason 3+4 with pattern 4 >50%, multiple intermediate factors
High: PSA >20 OR Gleason 8-10 OR T3-T4
Very High: T3b-T4, primary Gleason pattern 5, >4 cores with Gleason 8-10
USPSTF: Individualized decision age 55-69 (Grade C), โฅ70 not recommended (Grade D)
AUA: Baseline PSA at 40-55 for high risk (African American, family history)
PSA velocity: >0.75 ng/mL/year is concerning
PSA density: PSA/prostate volume >0.15 increases cancer suspicion
Free PSA: % free PSA <10% = higher cancer probability, 10-25% = intermediate, >25% = lower
Core Concepts
Hematuria Evaluation
Gross hematuria: โฅ3 RBCs/HPF on microscopic or visible blood. Etiologies: infection, stones, BPH, glomerular disease, malignancy, trauma, exercise, drugs. Risk stratification for urothelial carcinoma: High risk โ age >40, smoking history >15 pack-years, >25 RBCs/HPF, gross hematuria. Workup: CT urography (gold standard for upper tract), cystoscopy (mandatory), urine cytology. Low risk: <40 years, non-smoker, microscopic only โ consider renal ultrasound or repeat UA.
Urinary Tract Infections (UTI)
Uncomplicated cystitis: premenopausal, non-pregnant female. First-line: nitrofurantoin 100mg BID ร 5 days, TMP-SMX DS BID ร 3 days (if resistance <20%), fosfomycin 3g single dose. Complicated UTI: male, pregnancy, indwelling catheter, immunocompromised, structural abnormality. Pyelonephritis: fever, flank pain, CVA tenderness. Treatment: outpatient โ ciprofloxacin 500mg BID ร 7 days or levofloxacin 750mg daily ร 5 days (if local resistance <10%). Inpatient โ ceftriaxone or ciprofloxacin IV. Pregnancy: nitrofurantoin (avoid near term), amoxicillin-clavulanate, cephalexin.
Renal Colic & Stone Management
Calcium oxalate (70%), uric acid (10%), struvite (10%), cystine (5%). Non-contrast CT: gold standard. Size matters: <5 mm passes spontaneously (80%), 5-10 mm (medical expulsive therapy with tamsulosin), >10 mm needs intervention. Intervention: ESWL (extracorporeal shock wave lithotripsy) for <2 cm renal or proximal ureteral stones, ureteroscopy with laser lithotripsy, percutaneous nephrolithotomy for >2 cm or staghorn. Struvite stones: treat underlying UTI (Proteus, Klebsiella), may need complete removal.
Clinical Case Studies
Case 1: Elevated PSA and Prostate Cancer
Patient: 68-year-old male, PSA 8.2 ng/mL (previous 2.1 two years ago). No urinary symptoms. DRE: right lobe firm, nodular. PSA velocity = 3.05 ng/mL/year. Free PSA = 12%.
Diagnosis: Elevated PSA, abnormal DRE, low free PSA โ high suspicion for prostate cancer. MRI prostate: PIRADS 5 lesion in right peripheral zone. Targeted + systematic biopsy: Gleason 4+3=7 (Grade Group 3) in 6/12 cores, 80% cancer in positive cores. Bone scan: negative. CT abdomen/pelvis: negative for nodes.
Management: Intermediate-risk (unfavorable). Treatment options: radical prostatectomy (open, laparoscopic, or robotic-assisted) or external beam radiation therapy (IMRT) + androgen deprivation therapy (ADT) for 4-6 months. Active surveillance NOT appropriate. Post-prostatectomy: monitor PSA (undetectable expected), erectile rehabilitation, urinary continence training.
Case 2: Gross Hematuria
Patient: 55-year-old male, painless gross hematuria ร 2 weeks, clots. 30-pack-year smoker. No dysuria, no flank pain, no weight loss. UA: 200+ RBCs/HPF, no WBCs, no protein. Urine cytology: atypical cells.
Assessment: High risk for urothelial carcinoma (age >40, smoking history, gross hematuria, >25 RBCs/HPF).
Workup: CT urography: 2.5 cm enhancing lesion in right renal pelvis. Cystoscopy: normal bladder mucosa. Diagnosis: upper tract urothelial carcinoma. Treatment: radical nephroureterectomy with bladder cuff excision. Adjuvant chemotherapy based on final pathology (cisplatin-based if eligible). Surveillance: cystoscopy q3 months ร 2 years, then q6 months, then annually. CT chest/abdomen/pelvis every 6 months ร 2 years.
Case 3: Acute Urinary Retention
Patient: 75-year-old male, unable to void ร 12 hours, suprapubic pain, distended bladder. PMH: BPH ร 5 years, on tamsulosin. Post-void residual: 850 mL. PSA 4.5 ng/mL. Creatinine 1.4 mg/dL (baseline 0.9).
Diagnosis: Acute urinary retention secondary to BPH with post-obstructive diuresis risk.
Management: Immediate urethral catheterization (16-18 Fr Foley, or coude tip if resistance). Drain slowly (clamp after 500-1000 mL to prevent hematuria). Monitor for post-obstructive diuresis (polyuria after relief). Trial without catheter (TWOC) after 2-3 days with ฮฑ-blocker (tamsulosin 0.4mg daily). If recurrent retention or fails TWOC โ TURP (transurethral resection of prostate) or HoLEP (holmium laser enucleation). 5ฮฑ-reductase inhibitor (finasteride 5mg daily) if prostate >30g.
Practice Questions
A: Severe symptoms (20-35). Consider surgical intervention (TURP or HoLEP). If patient prefers medical therapy: combination ฮฑ-blocker + 5ฮฑ-reductase inhibitor. Evaluate for complications (retention, recurrent UTI, bladder stones, renal insufficiency).
A: Favorable intermediate risk (Gleason 3+4=7 with โค50% positive cores and only one intermediate-risk factor). Active surveillance is an option, or definitive treatment (surgery or radiation).
A: Nitrofurantoin 100mg BID ร 5 days or TMP-SMX DS BID ร 3 days (if local resistance <20%). Fosfomycin 3g single dose is an alternative. Fluoroquinolones should be reserved for complicated UTIs or allergies.
A: CT urography (CT with contrast, excretory phase). It visualizes the kidneys, ureters, and bladder. Cystoscopy is also mandatory to evaluate the bladder.
A: For stones >10 mm, ESWL has lower success rates for lower pole stones. Ureteroscopy with laser lithotripsy (URS) is preferred for 10-20 mm lower pole stones. PCNL is reserved for stones >20 mm or staghorn calculi.